Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure

Henry Krum, Emma Louise Ashton, Christopher Michael Reid, Victor Kalff, Jim Rogers, John Amarena, Bhuwan Singh, Andrew Maxwell Tonkin

Research output: Contribution to journalArticleResearchpeer-review

96 Citations (Scopus)


Background: Statins decrease mortality in patients with coronary artery disease. However, chronic heart failure (CHF) patients were often excluded in such trials. Statins possess pharmacologic properties (independent of cholesterol lowering) that may be beneficial on ventricular remodeling in such patients. Methods and Results: We conducted a 6-month randomized placebo (PBO)-controlled study of rosuvastatin (ROS) in patients with systolic (left ventricular ejection fraction [LVEF]
Original languageEnglish
Pages (from-to)1 - 7
Number of pages7
JournalJournal of Cardiac Failure
Issue number1
Publication statusPublished - 2007

Cite this